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Abstract: Over the last 15 years, low-molecular-weight heparins (LMWHs) have been 
accepted as the “gold standard” for pharmaceutical thromboprophylaxis in patients at high risk 
of venous thromboembolism (VTE) in most countries around the world. Patients undergoing 
major orthopedic surgery (MOS) represent a population with high risk of VTE, which may 
remain   asymptomatic or become symptomatic as deep vein thrombosis or pulmonary   embolism. 
  Numerous trials have investigated LMWH thromboprophylaxis in this population and dem-
onstrated high efficacy and safety of these substances. However, LMWHs have a number of 
disadvantages, which limit the acceptance of patients and physicians, especially in prolonged 
prophylaxis up to 35 days after MOS. Consequently, new oral anticoagulants (NOACs) were 
developed that are of synthetic origin and act as direct and very specific inhibitors of different 
factors in the coagulation cascade. The most developed NOACs are dabigatran, rivaroxaban, and 
apixaban, all of which are approved for thromboprophylaxis in MOS in a number of countries 
around the world. This review is focused on the pharmacological characteristics of apixaban 
in comparison with other NOACs, on the impact of NOAC on VTE prophylaxis in daily care, 
and on the management of specific situations such as bleeding complications during NOAC 
therapy.
Keywords: major orthopedic surgery, apixaban, dabigatran, edoxaban, rivaroxaban, deep vein 
thrombosis, venous thromboembolism, VTE prophylaxis
Introduction
Over the last 15 years, low-molecular-weight heparins (LMWHs) have been 
accepted as the “gold standard” for pharmaceutical thromboprophylaxis in patients 
at high risk of venous thromboembolism (VTE) in most countries around the 
world.1,2 Patients undergoing major orthopedic surgery (MOS) represent a population 
with high risk of VTE, which may be found asymptomatic in screening exams or 
  present as symptomatic events such as deep vein thrombosis (DVT) or pulmonary 
  embolism (PE). Numerous trials have investigated LMWH thromboprophylaxis 
in this population and demonstrated high efficacy and safety of these drugs.3–6 
However, LMWHs have a number of disadvantages. First of all, daily injections of 
parenteral anticoagulants are cumbersome and impair the quality of life of patients, 
especially in prolonged prophylaxis up to 35 days after MOS.7 Furthermore, allergic 
skin reactions are quite common, and cases of heparin-induced thrombocytopenia, 
however rare, demonstrate potentially life-threatening complications of heparin 
therapy. Therefore, frequent monitoring of platelet count is necessary during 
LMWH exposure.
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
139
REVIEW
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/TCRM.S24238Therapeutics and Clinical Risk Management 2012:8
Finally, LMWHs are derived from animal sources, and 
manufactures have faced changes in the processing methods 
and hygiene problems in the past. Consequently, production 
costs will remain comparatively high and might even increase 
in future.8 Some of these problems could be resolved by using 
the synthetic indirect factor Xa inhibitor fondaparinux, which 
has been shown to be highly effective in VTE prevention 
after MOS.9 On the other hand, fondaparinux also needs to 
be injected daily and, at least in some countries, is associated 
with high costs.
All of these problems with parenteral thromboprophylaxis 
provide the medical background for the development of new 
oral anticoagulants (NOACs). These are of synthetic origin 
and act as direct and very specific inhibitors of different fac-
tors in the coagulation cascade. The most developed NOACs 
are dabigatran, rivaroxaban, and apixaban, all of which are 
approved for thromboprophylaxis in MOS in a number of 
countries around the world, based on large Phase III trials 
demonstrating favorable efficacy and safety results compared 
with LMWH prophylaxis.10–16 Another factor Xa inhibitor, 
edoxaban, has also been tested in patients undergoing MOS 
but is currently not approved.17,18
This review is focused on the pharmacological char-
acteristics of apixaban in comparison with other NOACs 
and on the impact of apixaban on the management of VTE 
prophylaxis in patients undergoing MOS.
Pharmacological characteristics 
of apixaban and other new oral 
anticoagulants
Activation of factor X to factor Xa (FXa) plays a central 
role in the cascade of blood coagulation. FXa directly con-
verts prothrombin to thrombin through the prothrombinase 
  complex, which leads to fibrin clot formation and activation 
of platelets by thrombin. A single molecule of FXa is able to 
generate more than 1000 molecules of thrombin due to the 
amplification nature of the coagulation cascade. Furthermore, 
the reaction rate of prothrombinase-bound FXa increases 
300,000-fold compared with that of free FXa. Therefore, 
  factor X activation and binding in the prothrombinase com-
plex causes an explosive burst of thrombin generation.
New orally acting substances have been developed to 
inhibit FXa selectively (FXa inhibitors such as apixaban, 
rivaroxaban, or edoxaban), prevent this burst of thrombin 
generation, or inhibit the excessively generated thrombin 
(direct thrombin inhibitors such as dabigatran).
Apixaban is a small molecule with a molecular weight of 
460 Da, which inhibits factor Xa reversibly and   additionally 
inhibits trypsin and thrombin generation. In addition to 
inhibiting circulating factor Xa, apixaban also blocks factor 
Xa bound within the prothrombinase complex or factor Xa 
activity within the clot (Figure 1).19,20
After oral intake, apixaban is rapidly absorbed with 
bioavailability in the stomach and small intestine of 
approximately 66% and a high protein binding of 87%.21,22 
Maximum concentration levels are seen after 1–3 hours. 
The half-life of apixaban is 8–15 hours in young subjects 
after metabolism by a cytochrome P450 (CYP)3A4-related 
pathway with 25% renal excretion and 55% elimination by 
the feces (Table 1).23,24
The other new oral factor Xa inhibitors rivaroxaban 
(molecular weight of 436 Da) and edoxaban (molecular 
weight of 536 Da) were also found to inhibit free and clot-
bound factor Xa, which seems to be a class effect of all new 
oral factor Xa inhibitors.25,26 Of note, rivaroxaban does not 
inhibit other serine proteases such as trypsin.27
The bioavailability of rivaroxaban is approximately 100% 
with plasma protein binding above 90% and metabolism via 
CYP3A4-, CYP2C8-, and CYP-independent mechanisms. 
Thirty to forty percent of the substance is renally excreted 
as unchanged drug, whereas 30% is renally excreted as inac-
tive metabolits and the remainder is excreted as unchanged 
drug in the feces.28–31 The intestinal excretion appears to 
be mediated by p-glycoprotein (p-Gp) – an intestinal drug 
transporter – so potent p-Gp inhibitors may increase drug 
concentrations.32 The half-life ranges between 5 hours 
and 9 hours in healthy subjects and between 11 hours and 
13 hours in elderly subjects.33–36
Compared with apixaban and rivaroxaban, edoxaban 
has a lower bioavailability of around 50% and a half-life of 
9–11 hours in young healthy subjects with a combined elimina-
tion pathway: 35% is renally excreted (24% active metabolite) 
and 62% is excreted via feces.37–39 Edoxaban is also a substrate 
of p-Gp, so strong inhibitors could lead to a higher concentra-
tion of edoxaban.40 The metabolism in liver microsomes is 
mediated mainly by CYP3A4-related pathways.41
In contrast to these oral factor Xa inhibitors, dabigatran 
is an oral direct thrombin inhibitor (Figure 1), which binds 
to the active binding site of thrombin (free and clot-bound 
thrombin) and inhibits its activation. Dabigatran exhibits a 
pharmacological profile different from that of FXA inhibi-
tors (Table 1). Given as a prodrug (dabigatran etexilate), the 
substance is rapidly absorbed.42 However, dissolution and 
absorption require an acidic microenvironment, and there-
fore dabigatran etexilate capsules contain a core of tartaric 
acid to stabilize the variations in gastric pH. Despite this, 
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oral bioavailability is low with values around 6%. Peak 
plasma concentrations of dabigatran are reached approxi-
mately 2 hours after oral administration. Half-life in healthy 
  volunteers is 12–17 hours but prolonged in elderly patients or 
patients with impaired renal function, because nearly 90% of 
dabigatran is renally excreted. Dabigatran is not metabolized 
by CYP450 isoenzymes.
Drug-drug interactions of NOACs
With apixaban, pharmacological interactions are seen with 
comedications of azol-type antimycotics such as ketoconazol 
or HIV-protease inhibitors such as ritonavir, which result in 
an increase of the area under the curve and the maximum 
concentration for apixaban, potentially increasing bleeding 
risks. Therefore, apixaban treatment is contraindicated in 
patients receiving these drugs. Similar interactions are seen 
with rivaroxaban and edoxaban.35 On the other hand, coad-
ministration of rifampicin leads to a significantly lower area 
under the curve and thereby to a significantly lower efficacy 
of apixaban, rivaroxaban, or edoxaban, which needs to be 
considered because insufficient anticoagulant efficacy may 
result from this interaction.
In patients receiving dabigatran, concomitant treatment 
with strong p-Gp inhibitors like amiodaron,   verapamil,   chinidin, 
Intrinsic
coagulation
activation
Extrinsic
coagulation
activation
Binding in
prothrombinase
complex
Amplification
by 1000 times
Thrombin generation
IIa-inhibitors
(dabigatran)
Factor-X-inhibitors
(apixaban,
rivaroxaban,
edoxaban)
FXa F X
FVa
Ca2+
F IIa
Clot formation
F II
FXa
Figure 1 Simplified model of coagulation activation, clot formation, and mode of action of new oral anticoagulants. 
Notes: Intrinsic and extrinsic coagulation activation leads to activation of factor X (FXa), which is bound into the prothrombinase complex consisting of phospholipids, 
calcium (Ca2+), activated factor V (FVa), and FXa. Bound in this complex, a singe molecule of FXa can activate degredation of 1000 molecules of prothrombin (F II) to active 
thrombin (F IIa), which ultimately induces clot formation. Factor Xa inhibitors inhibit both free and complex-bound active factor Xa. On the other hand, direct thrombin 
inhibitors (factor II inhibitors) inactivate the thrombin generated by coagulation activation.
Table 1 Pharmacological profile of new oral anticoagulants: direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban and direct 
thrombin inhibitor dabigatran
Drug Rivaroxaban Apixaban Edoxaban Dabigatran
Target Xa Xa Xa IIa
VTE prophylaxis dose 10 mg OD 2.5 mg BID (Japan only: 30 mg OD) 220 mg OD (150 mg OD for CrCl 30–50 mL/min
Time and dosage of first  
application post surgery
6–10 h; 10 mg 12–24 h; 2.5 mg (Japan only: 6–8 h; 30 mg) 1–4 h; 110 mg (75 mg for CrCl 30–50 mL/min)
Bioavailability Up to 100% 66% 50% 6%
Half-life 5–13 h 8–15 h 9–11 h 12–17 h
Renal elimination 40% 25% 35% 85%
Interactions CYP3A4/p-Gp  
inhibitors
CYP3A4/p-Gp  
inhibitors
CYP3A4/p-Gp inhibitors p-Gp inhibitors
Abbreviations: BID, twice daily; CrCl, creatinine clearance; CYP, cytochrome P450; OD, once daily; p-Gp, p-glycoprotein; VTE, venous thromboembolism.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
141
VTE prophylaxis in major orthopedic surgeryTherapeutics and Clinical Risk Management 2012:8
or clarithromycin leads to higher plasma   concentrations of 
dabigatran, requiring a dose reduction. Furthermore, the 
combination of dabigatran and ketoconazole, ciclosporin, 
itraconazol, and tacrolimus is prohibited. Due to the reduction 
of dabigatran plasma concentrations, concomitant therapy 
with St Johns wort or rifampicin is not recommended.
Clinical trials of apixaban  
in major orthopedic surgery
Dose-response relationship and the safety of escalating doses 
of apixaban were tested in a trial comparing enoxaparin 
twice daily 30 mg subcutaneously, open-label warfarin 
target international normalized ratio (INR) 1.8–3.0, and six 
double-blind apixaban doses 5 mg,10 mg, and 20 mg daily 
as once- or twice-daily divided dose in patients undergo-
ing total knee replacement.43 Treatment lasted 10–14 days, 
commencing 12–24 hours after surgery with apixaban and 
enoxaparin and on the evening of surgery with warfarin. 
Usual exclusion criteria applied, and a mandatory bilateral 
venography was scheduled for Day 12 after the last study drug 
dose. Primary efficacy outcome was a composite of VTE and 
all-cause   mortality during treatment. Primary safety outcome 
was major bleeding, defined as reduction of hemoglobin 
. 2 g/dL and/or requirement of two units of packed red blood 
cells, need for discontinuing study medication, intracranial, 
retroperitoneal, intraspinal, or necessitating reoperation or 
intervention, intrapericardial or fatal. Minor bleeding were 
all events not meeting these criteria.
A total of 1217 patients were eligible for safety and 
856 patients for efficacy analysis. In all apixaban treatment 
arms, patients had lower primary efficacy event rates than 
either comparator (Figure 2). The primary outcome decreased 
with increasing apixaban dose. Efficacy outcome was 9.0% 
for 2.5 mg apixaban twice daily and 11.3% for 5 mg apixaban 
once daily, compared with 15.6% in the enoxaparin and 
26.6% in the warfarin group. Total VTE rates were lower 
in the twice-daily group than in the once-daily regimen. 
For the composite outcome of proximal DVT or PE and all-
cause mortality, each apixaban group had a lower event rate 
(0%–2.7%) compared with the enoxaparin group (4.6%), 
which was not statistically significant. For both once-daily 
and twice-daily apixaban regimens, a significant dose-related 
increase in the incidence of bleeding events was noted. 
  Incidence ranged from 0% (2.5 mg twice daily) to 3.3% 
(20 mg once daily). No major bleeding was observed in either 
the enoxaparin group or the warfarin group. Minor bleeding 
incidences during apixaban, enoxaparin, and warfarin treat-
ment were 0.7%–7.2%, 4.0%, and 5.3%, respectively. For 
patients receiving apixaban, rates of myocardial infarction 
(0.44%) and stroke (0.55%) were in line with other studies.
The authors concluded that 2.5 mg apixaban twice daily 
started 12–24 hours after surgery exhibits a favorable benefit-
risk profile compared with standards of care. Consequently, 
apixaban 2.5 mg twice daily was chosen in three large 
Phase III trials evaluating the efficacy and safety of apixaban 
thromboprophylaxis against standard of care enoxaparin.
In ADVANCE-1, the North American regimen of enox-
aparin 30 mg twice daily was tested against oral 2.5 mg 
  apixaban twice daily in elective knee replacement for 
10–14 days, started 12–24 hours post surgery.14 Primary 
efficacy outcome was a composite of asymptomatic and 
symptomatic DVT, nonfatal PE, and death from any cause 
during treatment. Definition of major bleeding was acute 
clinically overt bleeding accompanied by one or more of 
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Figure 2 Results of a Phase II dose-finding study of apixaban versus enoxaparin or international normalized ratio titrated warfarin in patients undergoing major orthopedic 
surgery.43 
Notes: All dosages of apixaban and both once- and twice-daily regimens were highly effective in venous thromboembolism prevention (left). Apixaban 2.5 mg twice daily had 
the lowest rates of major bleeding complications. Furthermore, increasing daily dosages led to a linear increase of bleeding complications in both once-daily and twice-daily 
regimens, but major bleeding complications were rare in all treatment arms (right).
Abbreviations: BID, twice daily; OD, once daily.
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the following: a decrease in hemoglobin concentration of 
2 g/dL or more during 24 hours, transfusion of two or more 
units of packed red blood cells, critical site bleeding (intrac-
ranial, intraspinal, intraocular, pericardial, or retroperitoneal 
  bleeding), bleeding leading to reoperation, intramuscular 
bleeding with compartment syndrome, or fatal bleeding.
Patients were followed for 60 days after anticoagulation 
therapy was stopped. In total, 1157 patients receiving apixa-
ban and 1588 patients receiving enoxaparin were included 
in the primary efficacy analysis. The rate of primary efficacy 
outcome was 9.0% with apixaban as compared with 8.8% 
with enoxaparin (relative risk [RR] 1.02 [95% confidence 
interval (CI) 0.78–1.32]). Secondary efficacy endpoint of 
major VTE event was seen in 2.1% and 1.6%, respectively. 
Of note, PE fatal and nonfatal occurred in 1.0% (apixaban) 
versus 0.4% (enoxaparin). Apixaban did not meet the pre-
specified statistical criteria for noninferiority, because event 
rates in both treatment arms were significantly lower than 
expected and the study was underpowered to prove noninfe-
riority for efficacy. Major bleeding events occurred in 0.7% 
with apixaban and 1.4% with enoxaparin (P = 0.053). The 
incidence of the composite safety endpoint major bleeding 
and clinically relevant nonmajor bleeding was 2.9% with 
apixaban and 4.3% with enoxaparin (P = 0.03). Other adverse 
events, such as hepatotoxicity and arterial thromboembo-
lism, were rare in both groups. The authors concluded that 
apixaban 2.5 mg twice daily and enoxaparin have a similar 
efficacy that is within limits and which should be acceptable 
to clinicians. Furthermore, apixaban was found to reduce the 
risk of bleeding complications.
In ADVANCE-2, patients undergoing elective uni- or 
bilateral total knee replacement were randomly allocated 
to receive oral apixaban 2.5 mg twice daily or enoxaparin 
40 mg subcutaneously once daily.16 Apixaban was started 
12–24 hours after wound closure and enoxaparin 12 hours 
before surgery, and both drugs were continued for 10–14 days 
when bilateral ascending venography was scheduled. Patients 
had follow-up assessments 30 days and 60 days after the last 
dose of study drug. The primary outcome was the composite 
of asymptomatic and symptomatic DVT, nonfatal PE, and all-
cause death during treatment. Bleeding events were classified 
as major, nonmajor, and clinically relevant nonmajor.
A total of 1528 patients were eligible for primary effi-
cacy analysis in the apixaban group, as were 1529 in the 
enoxaparin group. Primary outcome was reported in 15% of 
apixaban patients and 24% of enoxaparin patients (RR 0.62, 
95% CI 0.51–0.74, P , 0.0001). Major or clinically relevant 
nonmajor bleeding occurred in 4% of patients receiving 
apixaban and 5% of those treated with enoxaparin. Of nine 
major bleeding events with apixaban, five occurred before 
the first dose of apixaban. Elevated liver enzyme levels were 
equally reported in both study groups. The authors concluded 
that oral twice-daily 2.5 mg apixaban offers a convenient and 
more effective alternative to 40 mg enoxaparin daily without 
increased bleeding.
In ADVANCE-III, apixaban 2.5 mg twice daily was 
given 12–24 hours post surgery and tested against enoxaparin 
40 mg once daily, which was on the evening before surgery 
in patients undergoing hip replacement surgery.15 Both 
regimens were given for 35 days. Patients were   followed 
for 60 days after the last intended study drug dose. For all 
patients, bilateral venography was scheduled on Day 35. 
  Primary efficacy outcome was the composite of asymptom-
atic or symptomatic DVT, nonfatal PE, or death from any 
cause during the treatment period. Primary safety outcome 
was bleeding during treatment, defined as in the aforemen-
tioned studies.
Primary efficacy analysis was performed in 1949 
  apixaban-treated patients and in 1917 enoxaparin-treated 
patients. The primary efficacy outcome occurred in 1.4% and 
3.9% of patients, respectively (RR 0.36, 95% CI 0.22–0.54; 
P , 0.001 for both noninferiority and superiority). The com-
posite of outcome of major and clinically relevant nonmajor 
bleeding occurred in 4.8% versus 5.0% (P = 0.72). Hepatic 
enzyme elevations as well as arterial thromboembolic events 
were rare in both groups. The authors concluded that apixa-
ban at a dose of 2.5 mg twice daily was superior to enoxaparin 
at a dose of 40 mg per day, preventing one episode of major 
VTE for each 147 patients treated, without adding to the 
risk of bleeding.
Clinical impact of VTE prophylaxis 
with apixaban in major orthopedic 
surgery
General aspects of implementation of new 
oral VTE prophylaxis into daily practice
First of all, patients and staff need to be reminded that change 
of VTE prophylaxis from injectable drugs to oral anticoagu-
lants does not indicate that VTE is no longer a relevant risk 
and therefore that lower compliance is acceptable. On the 
contrary, because VTE risk remains high for weeks after hip 
or knee joint replacement, a daily administration of VTE 
prophylaxis is indispensable. It is known that patient compli-
ance with long-term prophylaxis decreases after discharge, if 
injectable anticoagulants are used.7 Therefore, the use of oral 
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anticoagulants should increase the acceptance of prolonged 
VTE prophylaxis, if patients are adequately instructed.
Secondly, hospital staff need to be aware that timing of 
the first dose of VTE prophylaxis is essential for the bal-
ance between effective VTE prevention and bleeding risks 
after major surgery. In contrast to LMWHs, which in many 
Western countries are started on the evening before surgery 
(in contrast to a postsurgical start in North America), the first 
dose of all new oral anticoagulants is given post surgery. 
However, the timing of the first dose of VTE prophylaxis post 
surgery depends on the substance used and needs to be care-
fully implemented. Historically, the parenteral anticoagulant 
fondaparinux has been shown to increase bleeding complica-
tions after MOS, if started before 6 hours post surgery, which 
leads to adjusted recommendations for fondaparinux.44
Based on these experiences, the timing of postsurgical 
oral thromboprophylaxis has been carefully considered. With 
apixaban prophylaxis, the first dose is given after 12–24 hours 
post surgery, allowing for a long time for primary hemostasis 
at surgical sites (Table 1). This is in contrast to other NOACs: 
dabigatran is started after 1–4 hours post surgery already, but 
with an initial dose of only 50% (110 mg instead of 220 mg, 
whereas rivaroxaban is started with a first full initial dose of 
10 mg after 6–10 hours post surgery).
Furthermore, timing of oral thromboprophylaxis and 
removal of spinal catheters is dependent on the NOAC in 
use, due to different half-lives, once- or twice-daily regimens, 
and a contraindication for dabigatran in patients with spinal 
catheters. Consequently, written standard operating proce-
dures should be implemented before thromboprophylaxis is 
switched from injectable agents to NOAC.
Finally, the duration of postoperative thromboprophylaxis 
after MOS is determined by the fact that VTE risk remains 
high for weeks after hip or knee replacement. Therefore, cur-
rent guidelines recommend prolonged thromboprophylaxis 
in these patients with a minimum of 10–14 days (Level 1B), 
but prolongation until Day 35 should be considered in MOS 
(Level 2B).45 However, these recommendations are similar 
for all types of medical thromboprophylaxis in use and do 
not differ with NOAC thromboprophylaxis.
Dose adjustments in special populations
For patients undergoing MOS, all new oral FXa inhibitors 
are currently contraindicated in patients with a creatinine 
clearance below 15 mL/min. Due to the low proportion of 
renal elimination of oral FXa inhibitors apixaban, edoxaban, 
and rivaroxaban, no dose adjustments are necessary if crea-
tinine clearance is above 15 mL/min. This is in contrast to 
  dabigatran, which is contraindicated at a creatinine   clearance 
below 30 mL/min. Furthermore, dose adjustments are neces-
sary in patients older than 75 years or with a creatinine clear-
ance between 30 mL/min and 50 mL/min (150 mg instead 
of 220 mg once daily).
Monitoring of NOAC thromboprophylaxis
Similar to the VTE prophylaxis with LMWH or fonda-
parinux, no routine monitoring of NOAC prophylaxis is 
necessary. All new oral anticoagulants display a predictive 
dose response, which allows for standard dosing indepen-
dent from laboratory test results. However, compared with 
LMWH or fondaparinux, an important difference exists. All 
oral FXa inhibitors produce a dose-dependent increase of 
prothrombin time (PT), INR, and clotting times.46,47 Of note, 
values need to be interpreted with caution, because standard 
measurements are not calibrated for these substances and 
short half-lives of FXa inhibitors would produce fast changes 
of test results within hours. Furthermore, a number of PT 
assays are available, which have vastly variable sensitivity 
to FXa inhibitors, and normal values as well as INR values 
above 3 may be found despite therapeutic anticoagulation. 
Consequently, interpretation of PT results would require 
specific calibration curves, the knowledge of the assay used 
to measure PT, and the exact timing of drug intake and blood 
sampling. This is in strict contrast to PT or INR measure-
ments during vitamin K antagonist therapy (VKA), where 
values remain fairly constant during the day and an INR 
range between 2 and 3 indicates adequate VKA treatment, 
while values outside of this range indicate a sub- or suprath-
erapeutic anticoagulant effect of VKA. Therefore, PT or INR 
monitoring is not recommended with oral FXa inhibitors. 
However, new tests are currently being implemented to allow 
for exact quantification of oral direct FXa inhibitors, based 
on the measurement of anti-FXa activity via chromogenic 
FXa assays.48–52
In contrast to the oral direct FXa inhibitors, dabigatran 
as a direct thrombin inhibitor significantly alters partial 
thromboplastin time (PTT) and, to a lesser extent, PT and 
INR values. Again, these changes must not be interpreted 
in a similar way to heparin or VKA therapy, because test 
results do not necessarily correlate with dabigatran therapy. 
Specific tests such as HemoClot are available to monitor 
dabigatran therapy.53
Taken together, neither normal nor abnormal test values 
of PTT, PT, INR, or clotting times give any indication of the 
quality of NOAC therapy, and interpretation of test results 
needs to reflect type and dosage of NOAC, interval between 
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intake and blood sampling, and renal and hepatic function. 
However, routine monitoring is not necessary for NOAC 
therapy, and specific tests will be available for the rare situ-
ations when management of emergency situations requires 
exact quantification of NOAC activity.
Management of bleeding complications
In Phase II, all NOACs exhibited a broad therapeutic window 
with only a slight increase in bleeding complications with 
higher dosages in dose-escalating studies in MOS.43,54–56 
These results were supported in large Phase III trials, where 
severe bleeding complications were rare. Consequently, most 
bleeding complications seen after MOS will not relate to the 
anticoagulant in use but rather to patient-specific factors or 
surgical complications. Furthermore, most bleeding complica-
tions will present as nonsevere bleeding, which can simply be 
managed by reducing or interrupting NOAC prophylaxis for a 
short period of time. Because all NOACs are short acting with 
half-lives comparable with LMWH prophylaxis, no change of 
standard of care is necessary in nonsevere bleeding situations. 
Obviously, standard management of bleeding complications 
may include local compression, surgical, endoscopic, or 
interventional therapy as well as hemodynamic stabilization 
with fluids or whole-blood transfusions.
In cases of severe bleeding, oral FXa inhibitor activity 
may be antagonized using prothrombin complex concentrates 
(PCC), recombinant factor VIIa (rVIIa), or factor eight 
inhibitor bypassing activator (FEIBA or aPCC).   Recombinant 
factor VII or FEIBA/aPCC may also be considered as treat-
ment options in severe bleeding complications of dabigatran-
treated patients.57,58
In case of suspected or suicidal overdosing of oral FXa 
inhibitors, gastrointestinal uptake can be reduced by activated 
carbon application within 3 hours after intake. In contrast, 
in patients receiving dabigatran, hemodialysis may reduce 
drug levels.58
The following steps provide a therapeutic guideline 
for patients with severe bleeding events: (1) delay the next 
administration of NOAC; (2) if the patient is treated with 
oral FXa inhibitors, consider activated carbon depending on 
the intake time; (3) if the patient is treated with dabigatran, 
consider hemodialysis; (4) consider usual treatment for 
bleeding, including endoscopic, surgical, or interventional 
bleeding control, blood transfusion, and fresh frozen plasma; 
and (5) if bleeding cannot be controlled or emergency surgery 
is indicated, consider administration of procoagulants such as 
PCC. If bleeding cannot be controlled, FEIBA or rVIIa may 
be used according to the guidelines. Of note, neither PCC 
nor rVIIa is approved for management of NOAC-associated 
bleeding complications.
Conclusion
Thromboprophylaxis in MOS is still an important issue, 
and the development of new oral anticoagulants has led 
to advances in both efficacy and safety in this indication. 
  Apixaban as one of the new oral direct FXa inhibitors 
has been shown to be highly effective and safe to prevent 
VTE complications in patients undergoing elective hip or 
knee replacement. Provided that personnel and patients 
are instructed that high treatment compliance is required, 
it can be expected that apixaban will achieve this benefit 
over parenteral prophylaxis also in unselected patients in 
daily care.
Implementation of NOACs in thromboprophylaxis in 
daily care is simple, but specific pharmacological differ-
ences exist between apixaban, rivaroxaban, and dabigatran. 
  Consequently, the choice of substance should reflect local 
specifics such as pre-existing experience with new oral anti-
coagulants, use of spinal catheters and timing of removal, pro-
portion of older or renally impaired patients, typically used 
comedications, and preference of a late postoperative start or 
a once-daily regimen. Therefore, the authors do not recom-
mend the use of different NOACs for thromboprophylaxis on 
the same orthopedic ward. Furthermore, we strongly recom-
mend the implementation of standard operating procedures 
for NOAC use in orthopedic surgery to enhance compliance 
and avoid errors in dosing and management problems (such 
as initiating prophylaxis too early or too late),  or catheter 
removal without interruption of NOAC, all of which may 
cause harm to the patient.
If oral FXa inhibitors such as apixaban are used in MOS 
prophylaxis, no dose adjustments for age, gender, or renal 
function are necessary, provided that renal function has 
a glomerular filtration rate above 15 mL/min. Furthermore, 
no routine monitoring is required.
Finally, major bleeding complications will be rare with 
NOAC thromboprophylaxis, and management of these 
will be comparable with that of bleeding complications in 
patients receiving LMWH prophylaxis, because all NOACs 
have predictable pharmacokinetics with comparatively short 
half-lives.
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